P/E ratio for TG Therapeutics (TGTX)
P/E ratio as of June 2024 (TTM): -91.4
According to TG Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -91.381. At the end of 2022 the company had a P/E ratio of -8.10.
P/E ratio history for TG Therapeutics from 2010 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -8.10 | 12.16% |
| 2021 | -7.22 | -66.81% |
| 2020 | -21.8 | 288.25% |
| 2019 | -5.61 | 214.49% |
| 2018 | -1.78 | -58.48% |
| 2017 | -4.29 | 46.8% |
| 2016 | -2.92 | -66.17% |
| 2015 | -8.64 | -12.68% |
| 2014 | -9.90 | 105.62% |
| 2013 | -4.81 | 233.33% |
| 2012 | -1.44 | 30842.05% |
| 2011 | -0.0047 | -99.98% |
| 2010 | -30.0 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Alkermes ALKS | 18.6 | -120.35% | 🇮🇪 Ireland |
 Dr. Reddy's RDY | 19.4 | -121.18% | 🇮🇳 India |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.